Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study by Sabel, Magnus et al.
CLINICAL STUDY
Birgitta Lannering and Barry Pizer have contributed equally.
  Magnus Sabel
magnus.sabel@vgregion.se
1 Department of Paediatrics, University of Gothenburg and 
Queen Silvia Children´s Hospital, Gothenburg, Sweden
2 Paediatrics III, Division of Paediatric Haematology and 
Oncology, University Hospital of Essen, Essen, Germany
3 Karolinska Institutet, Stockholm, Sweden
4 Department of Paediatrics, Adolescent and Young Adults 
Oncology, Institut Curie and University Paris Descartes, 
Sorbonne Paris Cité, Paris, France
5 Department of Radiooncology, University Hospital Leipzig, 
Leipzig, Germany
6 Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, 
Italy
7 Biocruces Health Research Institute, Universidad Del País 
Vasco/EHU, Bilbao, Spain
8 University Medical Centre Hamburg-Eppendorf, Hamburg, 
Germany
9 University of Würzburg, Würzburg, Germany
10 Northern Institute for Cancer Research, Newcastle 
University, Newcastle upon Tyne, UK
11 Department of Neuropathology, University of Bonn, Bonn, 
Germany
12 Alder Hey Children’s Hospital, Liverpool, UK
Received: 12 February 2016 / Accepted: 3 July 2016 / Published online: 16 July 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com
Relapse patterns and outcome after relapse in standard risk 
medulloblastoma: a report from the HIT-SIOP-PNET4 study
Magnus Sabel1  · Gudrun Fleischhack2 · Stephan Tippelt2 · Göran Gustafsson3 · 
François D z4 · Rolf Kortmann5 · Maura Massimino6 · Aurora Nav jas7 · 
Katja von Hoff8 · Stefan Rutkowski8 · Monika Warmuth-Metz9 ·  
Steven C. Clifford10 · Torsten Pietsch11 · Barry Pizer12 · Birgitta Lannering1 ·  
On behalf of the SIOP-E Brain Tumour Group
J Neurooncol (2016) 129:515–524
DOI 10.1007/s11060-016-2202-1
were extracted from the HIT Group Relapsed MB database 
and by way of a specific case report form. The event-free 
and overall (OS) survival at 10 yea s were 76 ± 2 % and
78 ± 2 % respectively with no significant difference between 
the treatment arms. Seventy-two relapses and three sec-
ond malignant neoplasms were reported. Thirteen relapses 
(18 %) were isolated local relapses in the posterior fossa 
(PF) and 59 (82 %) were craniospinal, metastatic relapses 
(isolated or multiple) with or without concurrent PF dis-
e s . Isolated PF re apse vs all other relapses occurred 
at mean/median of 38/35 and 28/26 months respectively 
(p = 0.24). Late relapse, i.e. >5  years from diagnosis, 
occurred in six patients (8%). Rel ps  treatment consisted 
of combinations of surgery (25 %), ocal radiotherapy 
(RT 22 %), high dos  chemotherapy with stem cell rescue 
(HDSCR 21 %) nd conventional chemotherapy (90 %). 
OS at 5 years after relapse was 6.0 ± 4 %. In multivariate 
analysis; isolated relapse in PF, and surgery were signifi-
cantly associated with prolonged survival whereas RT and 
HDSCR were not. Survival after relapse was not related 
to biological factors and was very poor despite several 
patients receiv ng intensive treatments. Exploration of new 
drugs is warranted, preferably based on tumour biology 
from biopsy of the relapsed tumour.
Keywords Medulloblastoma· Relapse · Survival · 
Treatment · Clinical trial · Chemotherapy · 
Radiothe apy · Paediat ic · Secondary tumours
Introduction
Th  5-year progression free survival for medulloblastoma 
(MB), the most common malignant brain tumour in child-
hood, is now expected to be 70–80 % in the ‘standard’ or 
Abstract The HIT-SIOP-PNET4 randomised trial for 
standard risk medulloblastoma (MB) (2001–2006) includ d 
338 patients and compared hyperfractionated nd conven-
tional radiotherapy. We here repor  the lo g- erm outcome 
after a median follow up of 7.8years, including detailed 
information on relapse and the treatme  of relap e. Data 
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For non-German patients, a case report form specifically 
designed for this analysis was sent to the treating institu-
tions asking for more detailed information on relapse site, 
symptoms and treatment of relapses and the date of death. 
For German patients, this information was collected from 
the HIT Group Relapsed MB database.
At primary diagnosis, tumour material was centrally 
reviewed by appointed study pathologists, confirming the 
diagnosis and the histological MB variant. In addition, a 
series of MB biomarkers were investigated as part of the 
HIT-SIOP-PNET4 study [6]; (i) β-catenin nuclear accu-
mulation by immunohistochemistry (IHC) and CTNNB1 
exon 3 mutation (DNA sequencing), which both defined the 
favourable-risk wingless (WNT)-activated MB subgroup [6], 
(ii) MYC and MYCN gene amplification status (by FISH), 
associated with a poor prognosis in previous studies [7], and 
(iii) Chromosome 17 alterations (Chr 17(im)/diploid back-
ground; by FISH), which were previously associated with a 
poor prognosis in the HIT-SIOP-PNET4 cohort [6].
Statistical methods
SPSS software was used for the statistical analyses (IBM 
SPSS Statistics, version 22, 2013, IBM Corp., Armonk, NY, 
USA). Relapse, SMN, death in remission and death after 
relapse were defined as events. The EFS and overall survival 
(OS) after relapse were estimated using the Kaplan–Meier 
method and differences in outcome between patients groups 
were tested using the Log Rank method. Comparisons of 
patient characteristics between subgroups were performed 
using Fisher’s exact test, Chi square test or ANOVA where 
appropriate. Prognostic factors after relapse were evaluated 
by using the Cox multivariate, proportional regression anal-
ysis. The significance level was set to p = 0.05.
Results
Long term survival of the patients included in the HIT-
SIOP-PNET4 study
At 10 years from diagnosis, EFS and OS for all the 338 
patients were 76 ± 2 % and 78 ± 2 % respectively. The EFS 
for the two treatment arms continued to show no signifi-
cant difference; HFRT 78 ± 3 %, STRT 76 ±3 % (Fig. 1a). At 
the time when data collection was halted, 72/338 patients 
(21 %) had suffered a relapse and three patients a SMN (see 
below). One patient died in CCR1. Four patients were lost 
to follow up.
In order to make our long term results comparable with 
the COG A9961 study [1], and only for this particular cal-
culation, two adjustments were made: 31 patients with large 
residual tumours >1.5 cm2 at diagnosis were excluded as 
‘average’ risk subgroup [1]. Betw e  2001 and 2006, the 
International Society of Paediatric Oncology (SIOP)-
Europe Brain Tumour Group conducted a multicentre Phase 
III trial, the HIT-SIOP-PNET4 study, for children and young 
people with ‘standard-risk’ MB, with >100 participat ng 
centres. After clinical staging, patients wer  randomised to 
receive either conventional/standard radiotherapy (STRT) 
or hyperfractionated radiotherapy (HFRT) f lowed by
chemotherapy. In addition, tumour biom rkers were exam-
ined [2]. We previously reported no significant difference 
in the probability of event free survival (EFS) be ween the 
two treatment groups after a median follow- p of 4.8 years 
[2]. The outcome after a media follow-up of 7.8 years is 
included in this report.
In standard risk MB, the major cause of death is due o 
relapse that occurs in 20−30 % of pat ents. Several reports 
have demonstrated that the prognosis at r lapse is po r, 
with generally less than 10 % survival [3–5]. This has 
caused uncertainty whether intensive second line treatment 
including re-irradiation or myeloablative chemotherapy 
is appropriate. In addition, here are increasing reports on 
the occurrence of second malignant neoplasms (SMN) as 
a consequence of MB therapy [1]. We he fore describe 
here the patterns of relapsed disease, treatments received at 
relapse as chosen by various institutions across Europe, and 
associated outcomes, for patients enrolled on the HIT-SIOP-
PNET4 study.
Patients and methods
Patients (n = 338) from Germany, France, Italy, UK, Aus-
tria, Spain, The Netherlands, Sweden, Norway and Den-
mark were included in the HIT-SIOP-PNET4 tria . Pa ients 
were 4–21 years of age, with a MB without metastases on 
craniospinal MRI or cerebrospinal fluid (CSF) cytology. All 
patients were randomised to receive either STRT (1.8 Gy 
daily) with 23.4 Gy to the craniospinal axis (CSA) and a 
30 Gy boost to the posterior fossa (PF) or HFRT (1 Gy twice 
daily) with 36 Gy CSA, a 24 Gy boost to the PF an  another 
8 Gy boost to the tumour bed. During RT, a weekly dose of 
vincristine was given. RT was followed by eight cycles of
chemotherapy with cisplatin, v ncristin and CCNU, given 
at 6 week intervals [2]. The study w s pproved by each 
national/institutional review board and all patients/parents/
guardians had consented to participate.
Until June 30th 2013, when the database was frozen, 
patients were followed to time of rel ps /progression 
(hereafter called relapse) or SMN as primary event. Time 
of relapse was defined as the date of radiological exami-
nation confirming the relapse. In Germany, MRI scans 
were centrally reviewed at relapse, in all other count ies 
radiological relapse was diagnosed at the treating centres. 
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Relapse site and timing
The 72 relapses occurred at a mean/median of 30/26 months 
from diagnosis; range 2–95 months. All patients had com-
plete radiological staging with cranial and spinal MRI at 
relapse. Metastatic CNS relapse with or without involve-
ment of the PF was the most common relapse site; 59/72 
patients (82 %), at a mean/median of 28/26 months after 
diagnosis. The majority of metastatic relapses, 47/59 (80 %), 
were multifocal, including cases with leptomeningeal dis-
semination. In the remaining 20 % there was a solitary meta-
static relapse in the spine (n = 7) or brain (n = 5) (Table 1). 
Eighteen relapses (25 %) were confined exclusively to the 
spine, and occurred at a mean/median of 30/26 months from 
diagnosis; range 9–65 months. Twelve of these were diag-
nosed by surveillance MRI. Eight (44 %) of the MRI scans
showing only spinal recurrence were centrally reviewed. 
There was information on CSF cytology in 61/73 patients. 
Twenty-one (34 %) had malignant cells in CSF at relapse, 
always in combination with other tumour manifestations. 
well as another 21 patients who had local but not central 
review of postoperative MRI performed which could allow 
for disseminated disease being missed. The adjusted EFS 
and OS at 10 years, were 79 ± 3 % and 81± 2 % (n = 286). 
All other results below are based on the total patient roup.
Diagnosis of relapse
MRI scans diagnosing relapse were centrally reviewed in 
29/72 cases (40 %). Information on the reason for perform-
ing the MRI that demonstrated relapse was available in 65 
patients (90 %). Forty-five relapses (69 %) were detected 
on surveillance MRI. For the remaining 20 patients wh s  
relapse presented symptomatically, the most common symp-
toms were headache and/or vomiting (n = 11), f ll wed by 
back pain (n = 5) a d loss of specific neurological function 
(n = 3). The patients presenting with symptoms had a signifi-
cantly shorter survival after lapse than those detected by 
surveillance MRI p <  0.01, but the OS (after primary diagno-
sis) did not differ p = 0.21 (Log Rank test).
Fig. 1 a Long-term probability of event free survival (EFS) of the 
two randomised treatment arms of HIT-SIOP-PNET4 at 5 and 10 years 
after primary diagnosis (Kaplan–Meier, Log Rank test). b Probability 
of overall survival (OS) after first re apse in the HIT-SIOP-PNET4 
cohort (Kaplan–Meier). c Probability of overall survival (OS) after 
first relapse in relation to site of relapse (Kaplan–Meier, Log Rank test)
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histology and biology on tumour material taken at relapse 
was not feasible.
Relapse treatment
In four patients no relapse treatment was given, (no treat-
ment data available in one patient). All remaining 67 
patients received treatment. The combination of treatments 
comparing those given to isolated PF vs all other relapses 
is shown in Table 1. Surgery was performed in 25 % with 
radical surgery in less than half of the procedures, RT in 
22 %, conventional chemotherapy in 90 % and HDSCR in 
21 % of all relapsed patients (Table 1). Surgery and HDSCR 
were significantly more often used (p = 0.027) in isolated PF 
relapses. Fifteen patients received re-treatment with focal RT 
(20-45 Gy), most often to spinal metastases (n = 10), supra-
tentorial localised relapse (n = 3) and PF = 2). The 
most common chemotherapy drug was temozolomide alone 
or in combination with other drugs. Carboplatin-based com-
binations were also common (Table 3).
Information on the use of intrathecal chemotherapy was 
available in 66 patients with 17 (26 %) r ceiving either eto-
poside (n = 7), methotrexate (n = 6), Depocyte™ liposomal 
cytarabine) (n = 3) and one unknown. Concordant informa-
tion on CSF cytology and intrathecal chemotherapy in 53 
patients showed that 9/21 (43 %) patients with CSF positiv-
ity received intrathecal treatment as did 5/32 (16 %) pa i n s 
without malignant cells in CSF.
Survival after relapse
The mean/median survival time after relapse was 
23/18 months (Fig. 1b). The OS after relapse, was 20 % 
(± 5 %) at 3 years, and 6 % (± 4 %) at 5 years after relapse. 
The OS after isolated PF relapse was significantly higher 
compared to all other relapses (p = 0.02) (Fig. 1c). In Cox 
multivariate analysis, surgery (p <  0.01) and isolated PF 
relapse (p <  0.01) were associated with longer survival after 
relapse unlike treatment with RT (p = 0.10) or HDSCR 
(p = 0.44). When the data base was frozen, nine patients 
were still alive. A detailed description of the survivors is 
shown in Table 4.
An isolated local relapse in PF was seen in 13 patie s 
(18 %) after a mean/median of 38/35 months. Late relapse 
i.e. >5 years from initial diagnosis, occurred in 6 patients 
(8 %). Five of these were isolat d relaps s in PF (n = 3) or 
spine (n = 2). There was no difference in relapse distribu-
tion (isolated PF vs not isolated PF) be w en early and la e 
relapses, although there was a rend for more ate, isolated 
PF relapses (p = 0.07, Fisher’s exact test). Late relapses we  
diagnosed by surveillance MRI in 2/6 and due to symp-
toms in 2/6, (2/6 no data). Neither the t min  nor the site 
of relapse differed between the two randomised treatment 
arms. Furthermore, we compared patients who received ≤4 
chemotherapy courses vs patients who received >4 (max 8) 
courses in the primary tumour tre t en , and found no sig-
nificant difference in the number of relapses between these 
two groups, (p = 0.398 Fisher’s exact test).
Relapse in relation to histology and biology at primary 
diagnosis
Histology at primary diagnosis (cl ssic 57, desmoplast c 
10, large cell/anaplastic 5) was not r lated to time in CCR1, 
(p = 0.56, ANOVA), localisation, (p = 0.97, Chi square) or
survival after relapse, (overall p = 0.32, Log Rank test). 
Nuclear β-catenin IHC status at diagnosis was known 
in 58/72 patients (14 % positive, 8/58 tumours as essed) 
and CTNNB1 mutation status in 55 (5 % mutated, 3/55), 
MYC/MYCN status in 33/72 patients (9 % MYCN mpli-
fied, 3/33, no MYC amplified), and chromosome 17 imbal-
ances/diploid background in 32/72 patients (ch17(im)/
diploid(cen); 31 %, 10/32) [6]. Neither nuclear β-catenin 
status nor Chr 17 status had any significant impact on time 
in CCR1, (p = 0.50/0.51 respectively, ANOVA), localisa-
tion (p = 0.61/0.07, Chi square) or survival after relaps , 
(p = 0.60/0.46, Log Rank test). Eight tumours showin  
nuclear beta-catenin accumulation relapsed, and n 4/8 of 
these other unfavourable risk factors w re pre ent (Tab e 2). 
Six of these relapses were previously r ported [6], wo more
patients have relapsed since that report. Notably, none of 
eight relapsed WNT-activated MBs is alive in remission 
(7 DOD). Only seventeen patients underwent surgery at 
relapse. Therefore, an analysis of outcome with respect to 
Site of relapse n (%) Surgery (%)RT (%) Chemother-
apy (%)
HDSCR (%)
Isolated PF 13 (18) 6/13 (46) 2/13 (15)11/11b (100)6/12a (50)
Isolated ST or spinal12 (17) 5/12 (38) 5/12 (38)8/8c (100)3/12 (25)
Multiple craniospinale ± PF 47 (65) 7/47 (14) 9/47 (19)41/41d (100)6/47 (13)
Total 72 (100)18/72 (25) 16/72 (22)60/66 (90) 15/72 (21)
HDSCR high dose chemotherapy with autologous stem cell rescue, PF pos erior fossa, RT adiotherapy, 
ST supratentorial
Information missing in a1 patient, b2 patients, c4 patients, d6 patients, ei cludes leptomeningeal 
dissemination
Table 1 Treatment of relapse 
according to site
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[1] which is very similar to our adjusted OS of 81 ± 2 %. 
The time to relapse, median 23 months, and the amount 
of disseminated relapses with a tendency to occur earlier 
than local PF relapses, is also in line with the COG study 
[1]. Consequently, the two largest studies of standard risk 
MB, including almost 700 patients, have produced very 
similar long-term results albeit using slightly different treat-
ment regimes. It is noteworthy that in both studies, patients 
who were not optimally staged at primary diagnosis (due 
to incomplete/poor quality MRIs or no central review of 
MRIs), or had excess residual tumour (>1.5 cm2) on review, 
had worse outcome [2, 8].
A relevant question today is whether the MB subgroup 
could explain the pattern and timing of relapse [1]. Ram s-
wamy et al. showed that the different MB subgroups 
had different relapse patterns, with more local relapses 
in patients with Sonic Hedgehog (SHH) tumours com-
pared to Group 3 and 4 tumours, which tended to relapse 
with metastases [9]. Furthermore, patients with Group 4 
tumours were shown to survive longer after relapse, com-
pared to the other subgroups [9]. In this study, only the 
WNT-activated subgroup could be prospectively delin-
eated, and insufficient tumour material remained to do 
further retrospective subgrouping. It is well known that 
tumours showing β-catenin nuclear accumulation (IHC) 
are prognostically favourable [10]. Indeed only eight 
patients with relapse showed this biomarker, however, the 
timing and pattern of relapse for WNT-activated tumours 
did not differ from the non-WNT tumours. The prognosis 
after relapse is poor also for this group, and frontline de-
escalation of therapy should only be done within trials, as 
salvage options are limited.
The majority of relapses were found on surveillance 
imaging when the patients had not yet developed signs or 
symptoms of relapse and seemingly these patients had a lon-
ger survival after relapse. This confirms previous findings 
but is probably due to the effect of lead time and length 
time bias as eventually almost all patients died due to pro-
gressive disease [3, 11]. The authors agree with others that 
with respect to survival, the benefit of early discovery of 
relapse by surveillance MRI remains unclear [12, 13], but 
could be justified in the perspective of possible inclusion 
in a relapse study, e.g. an early drug development trial. In 
that context, a spinal MRI should be considered, since 17 % 
of relapses were both asymptomatic and confined only to 
the spine. The high frequency of exclusively spinal recur-
rences (25 %) contrasts to a smaller study by Bartels et al., 
where 12/24 relapses had a spinal component but no exclu-
sively spinal relapses were found [12]. Admittedly, this dis-
crepancy could to some extent be explained by the lack of 
consistent central review of MRI scans in the present study, 
but since 8/18 (44 %) of cases with exclusive spinal relapse 
had a central review of the MRI scan, it seems that spinal 
Second malignant neoplasms (SMN)
Three SMNs were reported as primary events namely: a 
pontine anaplastic astrocytoma, a PF glioblastoma, a d an 
abdominal rhabdoid tumour in a child with Li-Fraumeni 
syndrome occurring 61, 55, and 35 mon hs after p imary 
diagnosis respectively. All three patients h v d ed. Review 
of the Li-Fraumeni case confirmed the original (desmoplas-
tic) MB diagnosis (INI-1 positive, SHH-activated with p53 
alteration).
Discussion
The primary aim of the HIT-SIOP-PNET4 s dy was  
compare two radiotherapy protocols. It was hypothesised 
that the HFRT regimen used woul  be superior f r urvival 
without causing more late effects. With a median follow 
up time of 7.8 years, the estimated OS at 10 years, remains 
not significantly different in the two treatment arms. Since 
some patients with standard risk MB are known to lapse 
later than 5 years after diagnosi i  this s udy 8 % of th  
patients), a long follow up is necessary to definitely accept 
the null hypothesis.
The Children’s Oncology Group (COG) A9961 RCT 
Study, published in 2012, comparing two different che-
motherapy protocols while giving the same conventional 
RT as in our study, reported a 10-year OS of 81.3 ± 2.1 %
Table 3 Chemotherapy and intrathecal treatment at relapse
Chemotherapy drugsNumber of patients
All 
patients
Isolated 
PF-relapses
Meta-
static 
relapses
Temozolomide 24 2 22
Carboplatin + etoposide ± cyclo-
phosphamide
15 3 12
Cyclophosphamide5 0 5
Trophosphamide + etoposide3 0 3
Temozolomide + ir notecan4 2 2
Gemcitabine + oxaliplatin2 0 2
Other combinations3 1 2
Drugs not specified 5 3 2
No chemotherapy 7 1 6
No data 4 1 3
Intrathecal chemotherapy drugs17
Etoposide 7
Methotrexate 6
Cytarabine 3
Other 1
No intrathecal chemotherapy49
No data 6
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and COMBAT [19, 20], with reports showing a degree of 
promise with respect to disease control.
The role of intrathecal therapy at relapse is difficult to 
evaluate. It was not used to its full extent in this study con-
sidering that less than half of the patients with malignant 
cells in CSF at relapse received this treatment. However, the 
non-randomised German HIT relapse study which involved 
the use of intraventricular etoposide prior and simultane-
ously to the conventional systemic chemotherapy showed 
short-term disease stabilisation in a relevant number of 
patients but did not achieve higher survival [21]. Re-irra-
diation, although not a factor for prolonged survival in the 
present study, has previously been shown to be of benefit, 
and considering the high frequency of metastatic relapses 
in MB, craniospinal re-irradiation has been suggested as a 
therapeutic option worth exploring, although this requires 
careful balancing against the risk of side effects [22].
A limitation of this study is the lack of information on 
tumour biology at relapse. This area is now being actively 
investigated. For example, Wang et al. demonstrated sub-
group stability across the primary and the metastatic com-
partments in newly diagnosed MB [23]. Ramaswamy et al. 
showed subgroup stability between tumour at diagnosis and 
relapse in MB [9] and Hill et al. recently undertook a com-
prehensive investigation of 29 relapsed MB that confirmed 
this finding [5]. Importantly, Hill et al. also demonstrated 
significant changes in biological characteristics of tissue 
at relapse compared to diagnosis. In particular, MYC fam-
ily (MYC, MYCN) gene amplifications and TP53 pathway 
defects commonly emerged in combination at relapse and 
predicted rapid progression to death [5]. Another limitation 
is that only 40 % of the relapses were confirmed by cen-
tral review of MRI scans, and also the diversity of relapse 
treatments.
The strength of this study is the long-time follow up of 
standard risk MB in children treated according to the same 
protocol in over one hundred European institutions. This 
would indicate an outcome not biased by treatment at few 
or tertiary centres. The report shows the outcome of relapse 
treatment without the use of a common protocol and gives 
a survival curve based on a variety of treatments to which 
further studies could be compared.
The optimal approach to treating relapsed MB in previ-
ously irradiated children remains in doubt. The question is 
still whether it is possible to identify a subgroup of patients 
in whom a curative approach is justified, and if this is pos-
sible, what therapy should be applied. Certainly, in cases 
where relapse is localised, surgical resection is appropriate. 
Surgery has added value with regard to provide material to 
enhance our understanding of this disease and to exclude 
a SMN. It appears clear however, that the vast majority 
of relapsed patients cannot be cured and in most patients 
exploration of new drugs in early phase trials is appropriate, 
relapses (leptomeningeal or solid) without concurrent cra-
nial involvement do occur.
We found a relatively low incidence of SMNs, with only 
three cases reported compared to he COG A9961 s udy 
from which fifteen cases were reported albeit with a few 
years longer follow up. We shou d thus expect mor SMNs 
and it appears that this is becomi g a major problem affect-
ing outcome as MB patients survive l nger [1]. However, 
some SMNs may have gone undetected due to the low num-
ber of tumour biopsies at relapse 17/72 (24 %), in th  pres
ent study.
The poor outcome after MB rel pse for patients previ-
ously treated with radiothe apy is in lin with oth r reports 
[3, 4, 11, 14, 15]. With regard to the use of HDSCR, there 
was hope that this approach would be of significant benefit 
in relapsed malignant brain tumours, and single institution 
reports showed encouraging results [16]. However, some
studies that reported surviva  from he time of HDSCR may 
particularly have over-estimated the benefit of HDSCR-
based strategies to the total population of r l psing pati nts. 
As noted in both the UK and Ge man ud es dis us ed 
below, a significant proportion of patients with chemo-
resistant disease may not reach HDSCR despite an initial 
treatment plan to include HDSCR with curative intent.
There have been only limited national studies specifically 
for relapsed MB that aimed to investigate treatment that 
may provide long-term disea e ontrol. In the UK CCLG 
relapsed PNET study (2000–2007), at a median follow-up 
of 7.4 years, only three MB pat ents were aliv , (5 year OS 
of 8.2 %) [15]. Similarly in 2014, Bo  t al. published the 
results of the German HIT-REZ-97 t ial [4]. This national 
study tested a non-randomised but stratified relapse protocol 
using either intensive chemotherapy +/- HDSCR as a poten-
tially curative therapy or o al chemotherapy as a palliative 
option. Survival was poor with only 2/72 patien s alive and 
in CCR at the time of the report. As of September 2015, 
these two patients are alive and in CCR 155 and 145 months 
after first relapse (G Fleischhack—personal communica-
tion). HDSCR was associated with s vere toxicity with a 
treatment related mortality ate of 7.4 %. The poor results of
a HDSCR-based approach have also been shown in recent 
small institutionally based studie  [17, 18]. To date there
has been no randomised trial evaluating the le of HDSCR 
in MB relapse in a multimodal therapy approach an  i
comparison with conventional chemotherapy, metronomic 
chemotherapy, targeted therapy or anti-angiogenic therapy.
As noted in this study, oral pa liative chemotherapy with, 
for example, temozolomide or etoposide wa frequently 
employed and may provide time-limited disease control
[14]. There has been recent interest in low intensity multi-
agent drug combinations with antiangiogenic effect often 
referred to as ‘metronomic chemotherapy’. In Europe, such 
therapy is being investigat d in studies such as MEMMAT 
1 3
523J Neurooncol (2016) 129:515–524
and define rapidly progressive, therapeutically targetable disease. 
Cancer Cell 27:72–84. doi:10.1016/j.ccell.2014.11.002
 6. Clifford SC, Lannering B, Schwalbe EC, Hicks D, O’Toole K, 
Nicholson SL, Goschzik T, Zur Muhlen A, Figarella-Branger D, 
Doz F, Rutkowski S, Gustafsson G, Pietsch T (2015) Biomarker-
driven stratification of disease-risk in non-metastatic medullo-
blastoma: results from the multi-center HIT-SIOP-PNET4 clinical 
trial. Oncotarget 6:38827–38839. doi:10.1 632/oncotarget.5149
 7. Ryan SL, Schwalbe EC, Cole M, Lu Y, Lusher ME, Megahed 
H, O’Toole K, Nicholson SL, Bognar L, Garami M, Hauser P, 
Korshunov A, Pfister SM, Williamson D, Taylor RE, Ellison DW, 
Bailey S, Clifford SC (2012) MYC family amplification and clin-
ical risk-factors interact to predict an extremely poor prognosis 
in childhood medulloblastoma. Acta Neuropathol 123:501–513. 
doi:10.1007/s00401-011-0923-y
 8. Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger PC, Rob-
ertson PL, Bayer L, LaFond D, Donahue BR, Marymont MH, 
Muraszko K, Langston J, Sposto R (2006) Phase III study of cra-
niospinal radiation therapy followed by adjuvant chemotherapy 
for newly diagnosed average-risk medulloblastoma. J Clin Oncol 
24:4202–4208. doi:10.1200/jco.2006.06.4980
 9. Ramaswamy V, Remke M, Bouffet E, Faria CC, Perreault S, 
Cho YJ, Shih DJ, Luu B, Dubuc AM, Northcott PA, Schuller U, 
Gururangan S, McLendon R, Bigner D, Fouladi M, Ligon KL, 
Pomeroy SL, Dunn S, Triscott J, Jabado N, Fontebasso A, Jones 
DT, Kool M, Karajannis MA, Gardner SL, Zagzag D, Nunes S, 
Pimentel J, Mora J, Lipp E, Walter AW, Ryzhova M, Zheludkova 
O, Kumirova E, Alshami J, Croul SE, Rutka JT, Hawkins C, 
Tabori U, Codispoti KE, Packer RJ, Pfister SM, Korshunov A, 
Taylor MD (2013) Recurrence patterns across medulloblastoma 
subgroups: an integrated clinical and molecular analysis. Lancet 
Oncol 14:1200–1207. doi:10.1016/s1470-2045(13)70449-2
10. Ellison DW, Onilude OE, Lindsey JC, Lusher ME, Weston CL, 
Taylor RE, Pearson AD, Clifford SC (2005) beta-Catenin status 
predicts a favorable outcome in childhood medulloblastoma: 
the United Kingdom Children’s Cancer Study Group Brain 
Tumour Committee. J Clin Oncol 23:7951–7957. doi:10.1200/
jco.2005.01.5479
11. Torres CF, Rebsamen S, Silber JH, Sutton LN, Bilaniuk LT, Zim-
merman RA, Goldwein JW, Phillips PC, Lange BJ (1994) Sur-
veillance scanning of children with medulloblastoma. N Engl J 
Med 330:892–895. doi:10.1056/nejm199403313301303
12. Bartels U, Shroff M, Sung L, Dag-Ellams U, Laperriere N, 
Rutka J, Bouffet E (2006) Role of spinal MRI in the follow-up 
of children treated for medulloblastoma. Cancer 107:1340–1347. 
doi:10.1002/cncr.22129
13. Saunders DE, Hayward RD, Phipps KP, Chong WK, Wade AM 
(2003) Surveillance neuroimaging of intracranial medulloblas-
toma in children: how effective, how often, and for how long? J 
Neurosurg 99:280–286. doi:10.3171/jns.2003.99.2.0280
14. Cefalo G, Massimino M, Ruggiero A, Barone G, Ridola V, Spre-
afico F, Potepan P, Abate ME, Mascarin M, Garre ML, Perilongo 
G, Madon E, Colosimo C, Riccardi R (2014) Temozolomide is an 
active agent in children with recurrent medulloblastoma/primi-
tive neuroectodermal tumor: an Italian multi-institutional phase 
II trial. Neuro Oncol 16:748–753. doi:10. 093/neuonc/not320
15. Pizer B, Donachie PH, Robinson K, Taylor RE, Michalski A, 
Punt J, Ellison DW, Picton S (2011) Treatment of recurrent 
central nervous system primitive neuroectodermal tumours in 
children and adolescents: results of a Children’s Cancer and Leu-
kaemia Group study. Eur J Cancer 47:1389–1397. doi:10.1016/j.
ejca.2011.03.004
16. Graham ML, Herndon JE 2nd, Casey JR, Chaffee S, Ciocci GH, 
Krischer JP, Kurtzberg J, Laughlin MJ, Longee DC, Olson JF, 
Paleologus N, Pennington CN, Friedman HS (1997) High-dose 
chemotherapy with autologous stem-cell rescue in patients with 
preferably guided by biopsies of the elapsed tumour, and 
not only the primary tumour.
Acknowledgments Th  contributions to this study f the SIOP-
Europe brain tumour group, national s udy group members, and 
national data managers are gratefully acknowledged. The study was 
presented in part at the International Symposium on Paediatric Neuro-
Oncology in Singapore 2014.
Funding Funding for this work was provided by: The Swedish Chil-
dren’s Cancer Foundation, The German Chi dren’s Cancer Founda-
tion, Cancer Research UK, The French M nistry of Health, The F ench 
National Cancer Institute (INCa) and Asso iazione Bianca Garavaglia 
onlus (B. Arsizio, Milano).
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict 
of interest.
Open Access Thi  article is distributed under the terms of th  
Creative Commons Attribution 4.0 International License (http://cre-
ativecommons.org/licenses/by/4.0/), which permits unrest icted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the ource, provide a 
link to the Creative Commons license, and indicate f changes were 
made.
References
 1. Packer RJ, Zhou T, Holmes E, Vezina G, Gajjar A (2012) Survival 
and secondary tumors in children with medulloblastoma re eiv-
ing radiotherapy and adjuvant chemotherapy: results of Chil-
dren’s Oncology Group trial A9961. Neuro Onc l 15:97–103. 
doi:10.1093/neuonc/nos267
 2. Lannering B, Rutkowski S, Doz F, Pizer B, Gustafsson G, Navajas 
A, Massimino M, Reddingius R, Benesch M, C rrie C, Taylor R, 
Gandola L, Bjork-Eriksson T, Giralt J, Oldenburger F, P etsch T, 
Figarella-Branger D, Robson K, Forni M, Clifford SC, Warmuth-
Metz M, von Hoff K, Faldum A, Mosseri V, Kortmann R (2012) 
Hyperfractionated versus convention l radiotherapy f lowed by 
chemotherapy in standard-risk medulloblastoma: results from the 
randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol 
30:3187–3193. doi:10.1200/jco.2011.39.8719
 3. Bouffet E, Doz F, Demaille MC, Tron P, Roche H, Plant z D, 
Thyss A, Stephan JL, Lejars O, Sariban E, Buclon M, Zucker JM, 
Brunat-Mentigny M, Bernard JL, Gentet JC (1998) Improving 
survival in recurrent medulloblastoma: earlier detection, bette  
treatment or still an impasse? Br J Canc r 77:1321–1326
 4. Bode U, Zimmermann M, Moser O, Rutkowski S, Warmuth-
Metz M, Pietsch T, Kortmann RD, Faldum A, Fleischhack G 
(2014) Treatment of recurrent prim tive neuroectodermal tumors 
(PNET) in children and adolescents w th high-dose chemo-
therapy (HDC) and stem cell support: results of the HITREZ 
97 multicentre trial. J Neurooncol 120:635–642. d i:10.1007/
s11060-014-1598-8
 5. Hill RM, Kuijper S, Lindsey JC, Petrie K, Schwalbe EC, Bark r 
K, Boult JK, Williamson D, Ahmad Z, Hallsworth A, Ryan SL, 
Poon E, Robinson SP, Ruddle R, Raynaud FI, Howell L, Kwok 
C, Joshi A, Nicholson SL, Crosier S, Ellison DW, Whart  SB, 
Robson K, Michalski A, Hargrave D, Jacques TS, Pizer B, Bailey 
S, Swartling FJ, Weiss WA, Chesler L, Cliff rd SC (2015) Com-
bined MYC and P53 defects emerge at medulloblastoma relapse 
1 3
524 J Neurooncol (2016) 129:515–524
(2012) Antiangiogenic metronomic therapy for children with 
recurrent embryonal brain tumors. Pediatr Blood Cancer 59:511–
517. doi:10.1002/pbc.24006
21. Tippelt S, Mikasch R, Warmuth-Metz M, Pietsch T, Hilger RA, 
Kwiecien R, Faldum A, Rutkowski S, Bode U, Siegler N, Fleis-
chhack G (2014) CT-002. Intraventricular therapy with etoposide 
in recurrent medulloblastomas, pineoblastomas, CNS-PNETs and 
ependymomas—final results of a phase II study. Neuro Oncol 
16:i10–i13. doi:0 1093/neuonc/nou066
22. Wetmore C, Herington D, Lin T, Onar-Thomas A, Gajjar A, 
Merchant TE (2014) Reirradiation of recurrent medulloblas-
toma: does clinical benefit outweigh risk for toxicity? Cancer 
120:3731–3737. doi:10.1002/cncr.28907
23. Wang X, Dubuc AM, Ramaswamy V, Mack S, Gendoo DM, 
Remke M, Wu X, Garzia L, Luu B, Cavalli F, Peacock J, Lopez 
B, Skowron P, Zagzag D, Lyden D, Hoffman C, Cho YJ, Eber-
hart C, MacDonald T, Li XN, Van Meter T, Northcott PA, Haibe-
Kains B, Hawkins C, Rutka JT, Bouffet E, Pfister SM, Korshunov 
A, Taylor MD (2015) Medulloblastoma subgroups remain stable 
across primary and metastatic compartments. Acta Neuropathol 
129:449–457. doi:10.1007/s00401-015-1389-0
recurrent and high-risk pediatric brain tumors. J Clin Oncol 
15:1814–1823
17. Gururangan S, Krauser J, Watral MA, Driscoll T, Larrier N, 
Reardon DA, Rich JN, Quinn JA, Vredenburgh JJ, DesjardinsA, 
McLendon RE, Fuchs H, Kurtzberg J, Friedman HS (2008) Effi-
cacy of high-dose chemotherapy or standard salvage therapy in 
patients with recurrent medulloblastoma. Neuro Oncol 10:745–
751. doi:10.1215/15228517-2008-044
18. Massimino M, Gandola L, Spreafico F, Biassoni V, Luksch R, 
Collini P, Solero CN, Simonetti F, Pignoli E, Cefalo G, Poggi 
G, Modena P, Mariani L, Potepan P, Podda M, Casanova M, 
Pecori E, Acerno S, Ferrari A, Terenzi ni M, Meazza C, Polastri
D, Ravagnani F, Fossati-Bellani F (2009) No salvage using high-
dose chemotherapy plus/minus reirradiation for relapsing previ-
ously irradiated medulloblastoma. Int J Radiat Oncol Biol Phys 
73:1358–1363. doi:10.1016/j.ijrobp.2008.06.1930
19. Sterba J, Pavelka Z, Andre N, Ventruba J, Skotakova J, Bajciova 
V, Bronisova D, Dubska L, Valik D (2010) Seco d complete 
remission of relapsed medulloblastoma induced by metronomic 
chemotherapy. Pediatr Blood Cancer 54:616–617. doi:10.1002/
pbc.22382
20. Peyrl A, Chocholous M, Kieran MW, Azizi AA, Prucker C, Czech 
T, Dieckmann K, Schmook MT, Haberler C, Leiss U, Slavc I 
1 3
